HIV/AIDS: Modified Stem Cells in the Spotlight

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2014 Feb 11

PMID 24509823

Citations 3

Authors

Enrique Armijo

Claudio Soto

Brian R Davis

Affiliations

Soon will be listed here.

Abstract

Since HIV/AIDS was first recognized in 1981, an urgent need has existed for the development of novel therapeutic strategies to treat the disease. Due to the current antiretroviral therapy not being curative, human stem cell-based therapeutic intervention has emerged as an approach for its treatment. Genetically modified hematopoietic stem cells (HSCs) possess the potential to self-renew, reconstitute the immune system with HIV-resistant cells, and thus control, or even eliminate, viral replication. However, HSCs may be difficult to isolate in sufficient number from HIV-infected individuals for transplantation and/or re-infusion of autologous HSCs preparations would also include some contaminating HIV-infected cells. Furthermore, since genetic modification of HSCs is not completely efficient, the risk of providing unprotected immune cells to become new targets for HIV to infect could contribute to continued immune system failure. Therefore, induced pluripotent stem cells (iPSCs) should be considered a new potential source of cells to be engineered for HIV resistance and subsequently differentiated into clonal anti-HIV HSCs or hematopoietic progeny for transplant. In this article, we provide an overview of the current possible cellular therapies for treating HIV/AIDS.

Citing Articles

Participation in HIV cure-related research: a scoping review of the proxy literature and implications for future research.

Dube K, Ramirez C, Handibode J, Taylor J, Skinner A, Greene S J Virus Erad. 2016; 1:250-256.

PMID: 26866059 PMC: 4745088.

Progress and prospects of engineered sequence-specific DNA modulating technologies for the management of liver diseases.

Nicholson S, Moyo B, Arbuthnot P World J Hepatol. 2015; 7(6):859-73.

PMID: 25937863 PMC: 4411528. DOI: 10.4254/wjh.v7.i6.859.

Lentivirus-mediated Gene Transfer in Hematopoietic Stem Cells Is Impaired in SHIV-infected, ART-treated Nonhuman Primates.

Younan P, Peterson C, Polacino P, Kowalski J, Obenza W, Miller H Mol Ther. 2015; 23(5):943-951.

PMID: 25648264 PMC: 4427875. DOI: 10.1038/mt.2015.19.

References

Hutter G, Thiel E . Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2. AIDS. 2010; 25(2):273-4. DOI: 10.1097/QAD.0b013e328340fe28. View

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

Ausubel L, Lopez P, Couture L . GMP scale-up and banking of pluripotent stem cells for cellular therapy applications. Methods Mol Biol. 2011; 767:147-59. DOI: 10.1007/978-1-61779-201-4_11. View

Gilliam B, Riedel D, Redfield R . Clinical use of CCR5 inhibitors in HIV and beyond. J Transl Med. 2011; 9 Suppl 1:S9. PMC: 3105509. DOI: 10.1186/1479-5876-9-S1-S9. View

Kennedy M, Awong G, Sturgeon C, Ditadi A, LaMotte-Mohs R, Zuniga-Pflucker J . T lymphocyte potential marks the emergence of definitive hematopoietic progenitors in human pluripotent stem cell differentiation cultures. Cell Rep. 2012; 2(6):1722-35. DOI: 10.1016/j.celrep.2012.11.003. View

Green M, Chen A, Nostro M, DSouza S, Schaniel C, Lemischka I . Generation of anterior foregut endoderm from human embryonic and induced pluripotent stem cells. Nat Biotechnol. 2011; 29(3):267-72. PMC: 4866999. DOI: 10.1038/nbt.1788. View

Zauli G, Re M, Davis B, Sen L, Visani G, Gugliotta L . Impaired in vitro growth of purified (CD34+) hematopoietic progenitors in human immunodeficiency virus-1 seropositive thrombocytopenic individuals. Blood. 1992; 79(10):2680-7. View

Anderson J, Javien J, Nolta J, Bauer G . Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy. Mol Ther. 2009; 17(12):2103-14. PMC: 2814390. DOI: 10.1038/mt.2009.187. View

Anderson J, Akkina R . CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection. Retrovirology. 2005; 2:53. PMC: 1199620. DOI: 10.1186/1742-4690-2-53. View

10.

Westby M, van der Ryst E . CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on. Antivir Chem Chemother. 2010; 20(5):179-92. DOI: 10.3851/IMP1507. View

11.

Bardini G, Re M, Rosti G, Belardinelli A . HIV infection and bone-marrow transplantation. Lancet. 1991; 337(8750):1163-4. DOI: 10.1016/0140-6736(91)92831-l. View

12.

Cen D, Zauli G, Szarnicki R, Davis B . Effect of different human immunodeficiency virus type-1 (HIV-1) isolates on long-term bone marrow haemopoiesis. Br J Haematol. 1993; 85(3):596-602. DOI: 10.1111/j.1365-2141.1993.tb03353.x. View

13.

Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K . Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009; 360(7):692-8. DOI: 10.1056/NEJMoa0802905. View

14.

Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E . Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood. 2010; 117(10):2791-9. DOI: 10.1182/blood-2010-09-309591. View

15.

Yao Y, Nashun B, Zhou T, Qin L, Qin L, Zhao S . Generation of CD34+ cells from CCR5-disrupted human embryonic and induced pluripotent stem cells. Hum Gene Ther. 2011; 23(2):238-42. DOI: 10.1089/hum.2011.126. View

16.

Masur H . The acquired immunodeficiency syndrome. Dis Mon. 1983; 30(1):1-48. DOI: 10.1016/0011-5029(83)90005-6. View

17.

Hanna J, Wernig M, Markoulaki S, Sun C, Meissner A, Cassady J . Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007; 318(5858):1920-3. DOI: 10.1126/science.1152092. View

18.

Wiedenheft B, Sternberg S, Doudna J . RNA-guided genetic silencing systems in bacteria and archaea. Nature. 2012; 482(7385):331-8. DOI: 10.1038/nature10886. View

19.

Perez E, Wang J, Miller J, Jouvenot Y, Kim K, Liu O . Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol. 2008; 26(7):808-16. PMC: 3422503. DOI: 10.1038/nbt1410. View

20.

Gaj T, Gersbach C, Barbas 3rd C . ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013; 31(7):397-405. PMC: 3694601. DOI: 10.1016/j.tibtech.2013.04.004. View